This phase I/II trial is evaluating the safety and effectiveness of an immunotherapy combined with a type of radionuclide therapy or external beam radiation therapy in patients with Merkel Cell Carcinoma that has spread to other parts of the body.
This trial is treating patients with Merkel Cell Carcinoma.
This is a systemic therapy and radiotherapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma
Other Non-Commercial Sponsor
Melanoma and Skin Cancer Trials Limited
Summary
All eligible patients will receive intravenous Avelumab at 10mg/kg every two weeks for 24 months or until unacceptable toxicity or evidence of disease progression. Depending on the group to which they are randomised, enrolled patients will either receive 177-Lu-DOTATATE treatment or external beam radiotherapy on 2 occasions, 8-10 weeks apart.
Recruiting Hospitals Read More